The round was led by IQVIA (NYSE: IQV) with participation from EW Healthcare Partners, Memorial Sloan Kettering Cancer Center and existing investors Boston Millennia Partners, Horizon Blue Cross Blue Shield of New Jersey, Hackensack Meridian Health and Atoc Holdings. With its participation in the Series C round, IQVIA has secured a seat on Cota’s board of directors.
The company intends to use the funds to scale its solutions across healthcare providers, payers and life sciences companies.
Led by John Hervey, chief executive officer, and Andrew Pecora, M.D., executive chairman, Cota is a healthcare data and analytics company that enables providers, payers and life science companies involved in diagnosing and treating complex diseases to optimize the outcomes of individual patients and lower the overall cost of the patient population served.
It is powered by the patented Cota Nodal Address™ (CNA) system, a digital classification methodology built by physicians and data scientists to precisely categorize patient factors, their diseases and intended therapies, enabling precision medicine at scale. The company’s real-world evidence sets are being used by life science companies to expand the application of precise clinical data to broaden the efficacies and lower the costs of clinical trials.
Cota’s technology enriches medical records to create research-grade data and joins it with a suite of analysis, visualization and management tools. This enables providers, payers and life science companies to analyze, report on and research outcomes, costs, treatments and quality at any granularity and stage of the patient journey.
FinSMEs
21/02/2018